{"id":"NCT00552058","sponsor":"UCB Pharma","briefTitle":"Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","officialTitle":"Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-10","completion":"2009-11","firstPosted":"2007-11-01","resultsPosted":"2010-12-30","lastUpdate":"2018-08-09"},"enrollment":439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn Disease"],"interventions":[{"type":"BIOLOGICAL","name":"certolizumab pegol (CDP870, CZP)","otherNames":["CIMZIA Â®","CDP870","CZP"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Certolizumab pegol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.","primaryOutcome":{"measure":"Percentage of Subjects in Clinical Remission at Week 6","timeFrame":"Week 6","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":31.6,"sd":null},{"arm":"Placebo","deltaMin":25.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":116,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Estonia","Finland","Germany","Hungary","Israel","Italy","Latvia","New Zealand","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":["21642014","26031921","25146586"],"seeAlso":["http://www.fda.gov/Safety/Recalls/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":223},"commonTop":["HEADACHE","NAUSEA","ABDOMINAL PAIN","PYREXIA","ARTHRALGIA"]}}